Obstructive Sleep Apnea is a chronic medical condition in which the upper airways become blocked during sleep, often leading to brief pauses in breathing. Nearly 30 million Americans are affected by OSA, and an estimated 80% of cases remain undiagnosed, according to the American Academy of Sleep Medicine. If left untreated, OSA is said to increase the risk of comorbidities, such as high blood pressure, heart failure, stroke, diabetes, dementia, chronic pain, and other debilitating, life-threatening diseases.
The company we are profiling today is Vivos Therapeutics Inc. (VVOS), a revenue-generating medical technology company developing non-invasive treatments for obstructive sleep apnea.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com